Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) had its price objective lifted by JMP Securities from $9.00 to $20.00 in a research report released on Tuesday morning. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on CRBP. Aegis restated a buy rating on shares of Corbus Pharmaceuticals Holdings in a report on Monday. Noble Financial restated a buy rating and issued a $19.00 price objective on shares of Corbus Pharmaceuticals Holdings in a report on Friday, November 11th. Finally, Cantor Fitzgerald restated a buy rating and issued a $17.00 price objective on shares of Corbus Pharmaceuticals Holdings in a report on Wednesday, October 26th.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded down 4.29% on Tuesday, hitting $7.80. 826,588 shares of the company’s stock were exchanged. The stock’s market cap is $341.23 million. Corbus Pharmaceuticals Holdings has a 12-month low of $1.01 and a 12-month high of $10.78. The company’s 50-day moving average price is $7.18 and its 200 day moving average price is $4.45.

In other Corbus Pharmaceuticals Holdings news, CFO Sean F. Moran acquired 17,900 shares of the stock in a transaction on Friday, August 26th. The shares were bought at an average cost of $3.92 per share, with a total value of $70,168.00. Following the transaction, the chief financial officer now owns 299,310 shares of the company’s stock, valued at approximately $1,173,295.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sean F. Moran acquired 148,960 shares of the stock in a transaction on Thursday, August 18th. The shares were acquired at an average cost of $3.32 per share, for a total transaction of $494,547.20. Following the completion of the transaction, the chief financial officer now directly owns 216,410 shares in the company, valued at approximately $718,481.20. The disclosure for this purchase can be found here. Company insiders own 11.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CRBP. Knoll Capital Management LP acquired a new position in shares of Corbus Pharmaceuticals Holdings during the third quarter valued at about $16,717,000. Fosun International Ltd acquired a new position in shares of Corbus Pharmaceuticals Holdings during the third quarter valued at about $4,753,000. BlackRock Institutional Trust Company N.A. increased its position in shares of Corbus Pharmaceuticals Holdings by 14.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 216,139 shares of the biopharmaceutical company’s stock valued at $1,468,000 after buying an additional 27,000 shares during the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Corbus Pharmaceuticals Holdings during the third quarter valued at about $508,000. Finally, Northern Trust Corp increased its position in shares of Corbus Pharmaceuticals Holdings by 41.0% in the third quarter. Northern Trust Corp now owns 45,436 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 13,222 shares during the last quarter. 25.39% of the stock is currently owned by institutional investors.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.